A series of structurally novel heterotricyclic α‐amino‐3‐hydroxyl‐5‐methyl‐4‐isoxazole‐propionate receptor‐selective antagonists
Authors:
Open Access
- 25 June 2010
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 160 (6) , 1417-1429
Abstract
Background and purpose: A new class of heterotricyclic glutamate analogues recently was generated by incorporating structural elements of two excitotoxic marine compounds, kainic acid and neodysiherbaine A. Rather than acting as convulsants, several of these ‘IKM’ compounds markedly depressed CNS activity in mice. Here, we characterize the pharmacological profile of the series with a focus on the most potent of these molecules, IKM‐159.Experimental approach: The pharmacological activity and specificity of IKM compounds were characterized using whole‐cell patch clamp recording from neurons and heterologous receptor expression systems, in combination with radioligand binding techniques.Key results: The majority of the IKM compounds tested reduced excitatory synaptic transmission in neuronal cultures, and IKM‐159 inhibited synaptic currents from CA1 pyramidal neurons in hippocampal slices. IKM‐159 inhibited glutamate‐evoked whole‐cell currents from recombinant GluA2‐ and GluA4‐containing α‐amino‐3‐hydroxyl‐5‐methyl‐4‐isoxazole‐propionate (AMPA) receptors most potently, whereas kainate and NMDA receptor currents were not reduced by IKM‐159. Antagonism of steady‐state currents was agonist concentration dependent, suggesting that its mechanism of action was competitive, although it paradoxically did not displace [3H]‐AMPA from receptor binding sites. IKM‐159 reduced spontaneous action potential firing in both cultured hippocampal neurons in control conditions and during hyperactive states in anin vitromodel of status epilepticus.Conclusions and implications: IKM‐159 is an AMPA receptor‐selective antagonist. IKM‐159 and related nitrogen heterocycles represent structurally novel AMPA receptor antagonists with accessible synthetic pathways and potentially unique pharmacology, which could be of use in exploring the role of specific populations of receptors in neurophysiological and neuropathological processes.Keywords
This publication has 54 references indexed in Scilit:
- High-Affinity Kainate Receptor Subunits Are Necessary for Ionotropic but Not Metabotropic SignalingNeuron, 2009
- Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonismMovement Disorders, 2008
- Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worseNeuropharmacology, 2007
- Neuroprotective and anticonvulsant effects of EGIS‐8332, a non‐competitive AMPA receptor antagonist, in a range of animal modelsBritish Journal of Pharmacology, 2007
- The AMPA Antagonist ZK 200775 in Patients with Acute Ischaemic Stroke: A Double-Blind, Multicentre, Placebo-Controlled Safety and Tolerability StudyCerebrovascular Diseases, 2005
- Cell Death and Synaptic Reorganizations Produced by SeizuresEpilepsia, 2001
- Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient miceNature, 1998
- Pharmacology and Regional Distribution of the Binding of 6‐[3H]Nitro‐7‐Sulphamoylbenzo[f]‐Quinoxaline‐2,3‐Dione to Rat BrainJournal of Neurochemistry, 1996
- Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines.Molecular Pharmacology, 1995
- The physiology of excitatory amino acids in the vertebrate central nervous systemProgress in Neurobiology, 1987